Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 98

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 98
---
. | CDC (2022). Gonorrhea                                                            
 Treatment Guidelines. https://www.cdc.gov/std/treatment-guidelines/gonorrhea.htm |

| 3. | WHO (2021). Antimicrobial Resistance in Gonorrhea. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance |

| 4. | Red Book Online (2024). Amphotericin B and AmBisome Pricing Data. |

| 5. | GoodRx (2024). Ceftriaxone                       
 Average Cost. https://www.goodrx.com/ceftriaxone |

| 6. | Drugs.com (2024). Mupirocin                                   
 Ointment Pricing. https://www.drugs.com/price-guide/mupirocin |

| 7. | CDC (2022). STD Surveillance                                            
 Report – Gonorrhea. https://www.cdc.gov/std/statistics/2022/default.htm |

| 8. | CDC (2020). Healthcare-Associated Infections (HAI) Reports – MRSA. |

| 9. | NIH/NIAID. Treatment Failures and Resistance Trends in MRSA. |

| 10. | Incidence,                                                                                                                  
 prevalence, and management of MRSA bacteremia across patient populations—a review of recent developments in MRSA management 
 and treatment, Critical Care. Hassoun et al, Aug 2017                                                                       |

<div align='center'>62

Our Second Lead Candidate, Nano-Candesartan (nanoparticles-based ARB), is being developed for combination

therapy with an initial indication in pancreatic ductal adenocarcinoma (PDAC).</div>

The Company’s next drug candidate is
another novel nanoparticles-based formulation of angiotensin receptor blockers (ARBs), also known as AT1 receptor blockers (AT1) for
intravenous (IV) administration – Nano-Candesartan.

The Company holds an exclusive option to obtain
an exclusive, worldwide license for the development, manufacturing, and commercialization of products incorporating the technology underlying
the novel liposomal Angiotensin Receptor Blocker (ARB) formulation. The option must be exercised within 90 days following receipt of
the final scientific report, after which the parties have up to 120 days to negotiate the definitive licensing agreement. As part of
this process, the Company plans to conduct large animal safety studies in the fourth quarter of 2025 to support its decision on whether
to